Kevin Thompson
Rheumatology · Corpus Christi, TXNPI 1043772999
Payments from drug & device makers
Across 253 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$864
- AbbVie$652
- AstraZeneca$530
- Johnson & Johnson$452
- Aurinia Pharma U.S., Inc.$388
- UCB, Inc.$360
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,99798%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 44 | $864 |
| AbbVie | 41 | $652 |
| AstraZeneca(2 entities) | 24 | $530 |
| Johnson & Johnson | 15 | $452 |
| Aurinia Pharma U.S., Inc. | 31 | $388 |
| UCB, Inc. | 15 | $360 |
| Novartis | 10 | $231 |
| Sanofi | 2 | $201 |
| Fresenius Kabi USA, LLC | 8 | $194 |
| ANI Pharmaceuticals, Inc. | 11 | $186 |
| Radius Health, Inc. | 8 | $172 |
| Organon | 5 | $127 |
| Mallinckrodt Hospital Products Inc. | 6 | $125 |
| Pfizer | 7 | $119 |
| Genentech USA, Inc. | 5 | $82 |
| Lilly USA, LLC | 4 | $74 |
| Boehringer Ingelheim | 2 | $44 |
| GSK | 2 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Sobi, Inc | 2 | $40 |
| Teleflex LLC | 2 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $27 |
| Merck | 1 | $27 |
| Octapharma USA, Inc. | 1 | $20 |
| Ambu Inc. | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$134
- Tremfya$134
- SAPHNELO$104
How this compares
$5,076 in reported general payments places this provider in the 45th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 13 | $90,537 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $81,691 |
| MethotrexateMethotrexate Sodium | 35 | $865 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 22 | $622 |
| Prednisone | 46 | $465 |
| Hydroxychloroquine Sulfate | 23 | $392 |
| Leflunomide | 13 | $241 |
| Pregabalin | 17 | $116 |
| Tramadol Hcl | 12 | $39 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Corpus Christi
- Adriana Pop MoodyCorpus Christi$598K
- Eric ChiangCorpus Christi$423K
- Paul PickrellAustin$40.9M
- Atul SinghalMesquite$13.9M
- Shaikh AliTomball$9.8M
- Jitendra VasandaniLubbock$6.4M
- Dhiman BasuColleyville$6.2M
- Tamar BrionezThe Woodlands$5.2M
- Philip WallerHouston$4.9M
- John CushDallas$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.